Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Your doctor can discuss this with you in more detail
In a study of over 17,000 people, semaglutide, a GLP-1 receptor agonist medication, was found to lower the risk of cardiovascular events like heart attacks and strokes by 20% in people who have pre-existing cardiovascular disease and who are overweight, but do not have Type 2 diabetes
Semaglutide mimics a natural hormone called GLP-1, helping to curb appetite and encourage sustainable weight loss
Coverage may require prior authorization, lab results, diagnosis details, or proof that other medications were tried first
,aspect=ignore)
US$ 29.80
,aspect=ignore)
US$ 22.27
US$ 25.34
US$ 21.22
,aspect=ignore)
US$ 26.06
